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An open, crossover and randomized study was carried out to compare the safety and efficacy of salbutamol inhaled 
using the dry-powder inhaler Turbuhalers, and using a pressurized metered-dose inhaler (pMD1). Twelve patients 
with moderate to severe asthma, aged 47-68 years, were included in the study. On two separate days, patients 
received a total dose of 16OOpg of salbutamol administered in a cumulative dose fashion: 100, 100, 200, 400 and 
SOOpg at 3-min intervals. 
Salbutamol inhaled via Turbuhaler caused a larger decrease in serum potassium concentration than did 
salbutamol inhaled via pMD1. The estimated relative dose potency of the hypokalaemic effect of salbutamol 
Turbuhaler vs salbutdmol pMD1 was 2.0 with a 95% confidence interval of 1.3-3.6. Turbuhaler caused a small (but 
statistically significantly greater than with pMD1) increase in heart rate, QTc interval and tremor. Blood pressure 
was unaffected by the treatments. No adverse events of clinical relevance were reported. The estimated relative dose 
potency of the bronchodilating effect (FEV,) of salbutamol Turbuhaler vs salbutamol pMD1 was 3.0 with a 95% 
confidence interval of 1.8858. 
In conclusion, salbutamol inhaled via Turbuhaler was more potent and seemed to have a better therapeutic ratio 
than salbutamol inhaled via pMD1. Both treatments were equally well tolerated. 
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Introduction 
Inhaled short-acting &-agonists have played an important 
role in the management of asthma for more than two 
decades. Their immediate bronchodilating effect makes 
them the medication of choice for treatment of acute 
asthma attacks and for pre-treatment of exercise- and 
allergen-induced bronchoconstriction (1). Salbutamol, a 
relatively selective j&-agonist (2) is well established in the 
treatment of reversible obstructive airway diseases. The 
predominantly used formulation of inhaled salbutamol has 
been the chlorofluorocarbon (CFC)-propelled pressurized 
metered-dose inhaler (pMD1). Turbuhaler K: (Astra Draco), 
an inspiratory-flow-driven, multidose, dry-powder inhaler 
delivers micronized drug without the need of propellants 
(3). When using Turbuhaler, patients do not need to 
co-ordinate dose acutation with inhalation of the drug; a 
problem which is commonly associated with the use of 
pMDIs and which may influence patient compliance 
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and drug efficacy (4,5). A previous study showed that 
Turbuhaler delivers about twice the amount of terbutaline, 
another short-acting &agonist, to the lungs as the corre- 
sponding pMD1, and that the observed difference in 
deposition is reflected in the bronchodilating effect of 
terbutaline (6). 
In general, &agonists are well tolerated and have 
sufficient safety margins even at high doses. However, at 
doses higher than 50O,~g, inhaled salbutamol has been 
shown to cause extrapulmonary effects, such as changes 
in blood pressure, increased heart rate, tremor and 
hypokalaemia (7). 
The aim of this study was to determine the relative dose 
potency, with regard to safety and efficacy, of the new drug 
formulation, salbutamol Turbuhaler, vs salbutamol pMD1 
in patients with asthma. 
Patients and Methods 
PATIENTS 
Twelve outpatients (three women) with reversible airways 
obstruction were included in the study (Table 1). They had 
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TABLE 1. Patient characteristics at inclusion and medication taken during the study period 
Smoking habits Baseline Baseline Duration 
Patient Age (ex-, current or FEV, FEV, of asthma Disease(s) other 













68 Ex- 1.53 54 14 
61 Ex- 1.54 49 6 
54 Ex- 1.00 36 47 
56 Current 1.38 44 5 
63 Current 1.67 49 3 
64 Ex- 1.08 36 6 
61 Current 1.08 47 10 
50 Ex- 2.91 79 4 
41 Current 2.00 46 12 
65 Ex- 1.56 52 5 
53 Ex- 1.82 60 12 
60 Non- 1.05 49 11 
IP, 1s 
m 1s 
Chronic bronchitis Ip 
Hypertension I/3, IS, calcium 
antagonist 
ID> 1s 
Hypertension, gout IB, calcium antagonist, 
allopurinol 
IP 




Hypertension I/?, IS, diuretic 
ID, inhaled /&-agonist; IS, inhaled steroid. 
a mean age of 59 years (range: 47-68), a mean baseline 
forced expiratory volume in 1 s (FEV,) of 50% (range: 
36-79) of predicted normal value, and a mean reversibility 
of FEV, of 20% (range: 15-26) measured 15 min after 
inhalation of 2OOpg of salbutamol. Seven patients were 
former smokers, four were current smokers and one had 
never smoked. 
Patients were not included if they had a theophylline 
serum level >28 pm011 - i. Hospitalization for treatment of 
airway disease within 1 month or significant disorders other 
than airway disease also disqualified patients from inclusion 
in the study, as did pregnancy, breast-feeding or active 
planning of pregnancy. Concomitant &-agonist medication 
was withheld as follows: inhaled short-acting, 8 h; inhaled 
long-acting, 24 h; and oral, nebulized or parenteral, 36 h 
prior to and throughout the study. Oral steroids were not to 
be used within 30 days prior to enrolment, and patients 
using orally or nasally inhaled steroids were to keep the 
dose constant 30 days prior to and throughout the study. 
The patients were allowed to use salbutamol pMD1 as 
rescue medication at any time during the study, except 
within 8 h prior to the baseline spirometry at the enrolment 
visit and on the two study days. 
The study was performed in accordance with the 
principles stated in the Declaration of Helsinki and 
the principles of Good Clinical Practice adopted by the 
European Community. It was approved by the Swedish 
Medical Products Agency and the Ethics Committee at the 
University of Gothenburg. The patients gave their signed 
informed consent before they were enrolled in the study. 
STUDY DESIGN 
The study was of an open, crossover and randomized 
design. Patients received cumulative doses of salbutamol: 
100, 100, 200, 400 and 8OOpg at 30-min intervals, using 
Turbuhaler (Astra Draco) or pMD1 (Glaxo), on two study 
days separated by at least 24 h. Inspiratory flow through 
Turbuhaler and pMD1 was measured by connecting the 
inhalers one at a time in a serial mode to a Vitalograph 
MD1 modified Compact spirometer (Vitalograph Ltd, 
U.K.). Patients inhaled salbutamol while in a sitting, 
upright position. When using Turbuhaler, they were 
instructed to inhale deeply and forcefully. When using 
pMD1, they were instructed to inhale as slowly as possible 
and to actuate the dose at the beginning of the full 
inhalation. After completed drug inhalation, the patients 
were asked to hold their breath for 10 s. Patients practised 
the inhalation manoeuvres at the enrolment visit using 
empty Turbuhaler inhalers and placebo pMDIs. 
Baseline measurements were made within 30 min before 
the first study drug administration on each study day. 
Blood pressure was then measured at 15 min after each dose 
using a standard sphygmomanometer. Readings were taken 
with the patient in the sitting position after a 5-min rest. 
Heart rate was measured over consecutive 5-min intervals 
between 10 and 30 min after each dose in a continuous 
three-lead electrocardiogram (Marquette Series 8500 Holter 
recording). The QT interval was measured at 15 and 25 min 
after each dose in five consecutive QRS complexes using a 
Siemens Elema Mingograf. The QT interval was corrected 
for heart rate (QTc) according to Bazett (8). Subjective 
tremor was estimated on a four-point scale (O=no tremor; 
1 =just perceivable; 2=perceivable; 3 =troublesome;) at 
20 min after each dose, followed by an objective tremor 
measurement using a one-plane accelerometer applied to 
the patient’s right-hand middle finger (9). During the 
measurement, the patient’s wrist rested on the table and 
the finger was held moderately stretched. Acceleration in 
the up-down direction was measured during 5 x 10 s using 
an accelerometer connected to an analogue pre-amplifier 
(Anglo Devices), a Macintosh II computer with an 
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TABLE 2. Mean baseline values (range) of extrapulmonary variables 
Turbuhaler pMD1 
Blood pressure 
Systolic (mmHg) 112 (90-150) 111 (85-155) 
Diastolic (mmHg) 72 (60-80) 71 (60-85) 
Maximum heart rate (bpm) 87 (755101) 87 (67-108) 
QTc interval (ms) 400 (380420) 390 (36@410) 
Tremor (units) 4.3 (2.3-7.6) 4.2 (2.2-7.1) 
Serum potassium (mm01 1 - ‘) 4.3 (3.885.4) 4.3 (3.94.9) 
A/D-converter board NB- MI016L (National Instruments) 
and the software package LabVIEW (National Instru- 
ments). The accelerometer signal was analysed by Fast 
Fourier Transformation to achieve the frequency spectrum. 
The spectrum was integrated in 20 intervals of 2.5 Hz each 
with a sampling speed of 100 Hz. Tremor was then calcu- 
lated by totalling the integrals for 2.5-12.5 Hz, i.e. the range 
of maximum amplitude demonstrated previously for 
physiological tremor and tremor induced by intravenous 
terbutaline in healthy volunteers (unpubl. obs.), and by 
dividing the sum by 1000. Tremor was expressed as tremor 
units calculated as the sum of these integrated values. For 
determination of serum potassium concentration, venous 
blood was collected at 23 min after each dose. Serum was 
analysed using an ion-selective electrode method (10,ll) 
and the COBAS MIRA S instrument (Roche Diagnostics, 
Switzerland) fitted with an ion exchange module. Lung 
function variables, FEV, and forced vital capacity (FVC), 
were measured at 25 min after each dose and, in accordance 
with recommendations by the American Thoracic Society 
(12), were measured using a Vitalography Compact spirom- 
eter (Vitalograph Ltd, U.K.). Adverse events were assessed 
by means of a standard question addressed to the patients 
at 60 min after the last dose on each study day, in the 
morning following each of the two study days and at 
the follow-up visit. 
STATISTICAL METHODS 
The change from baseline for each patient and treatment 
was calculated for blood pressure, heart rate and QTc. 
Analysis of variance (ANOVA) was used to determine 
whether there was any difference in mean response 
between the two inhalers. A probability level of less 
than 5% was considered significant. Tremor, serum 
potassium and lung function variables (FEV, and 
FVC) were analysed under the following model: mean 
effect = patient +inhaler + period+ln(dose). When possible, 
period adjusted means were approximated with straight, 
parallel lines and scaled to percentage increase from the 
mean baseline on the two study days. The relative dose 
potency factor was estimated as eD”, where D is the 
estimated difference between the inhalers (the horizontal 
distance between the parallel lines) and b is the coefficient 
of the regression parameter ln(dose). A 95% confidence 
interval for the relative dose potency factor was computed 
using Fieller’s method (13). A relative dose potency factor 
of 1.0 means that there is no difference between the two 
inhalers. 
Results 
Peak inspiratory flow was, on average, 64 1 min ~ ’ (range: 
5472) when using Turbuhaler and 40 1 min - ’ (range: 
26-54) when using the pMD1. Mean inhalation volume 
ranged between 1.8 and 4.8 1 when using Turbuhaler and 
between 1.1 and 5.0 1 when using pMD1. Breath-holding 
was longer than 5 s in all cases except one (2.5 s). 
There was no difference between the two study days with 
regard to baseline values of extrapulmonary variables 
recorded prior to study drug administration (Table 2). 
CARDIOVASCULAR EFFECTS 
Systolic and diastolic blood pressures remained unchanged 
after inhalation of salbutamol via Turbuhaler or pMD1, 
even at the highest dose level. Salbutamol inhaled via 
Turbuhaler caused a larger increase in heart rate than did 
salbutamol inhaled via pMD1 (P<O.OOOl). Maximum heart 
rate was reached between 25 and 30 min after the last dose 
on each study day. Mean of the maximum values recorded 
within this interval was 95 beats min - ’ (range: 78-109) for 
Turbuhaler and 89 beats min - i (range: 76-106) for pMD1. 
Salbutamol slightly lengthened the QTc interval. Although 
small, the effect was more pronounced with Turbuhaler, 
than with pMD1 (P<O.OOl). Assuming parallel profiles, the 
difference between the inhalers was estimated to 11 ms with 
a 95% confidence interval of 5-16 ms. Individual QTc 
intervals were considered normal, i.e. less than 430 ms for 
men and less than 450 ms for women (14), at all dose levels 
except in one case (a prolonged QTc interval of 460ms, 
followed by a normal QTc interval of 420 ms, was observed 
for one male patient after cumulative doses of 800 and 
1600 ,ug, respectively, inhaled via Turbuhaler). 
TREMOR 
Tremor was experienced by four patients, one of whom 
reported tremor after each Turbuhaler dose, as well as after 
the highest cumulative dose (16OOpg) inhaled via pMD1. 
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FIG. 1. Mean values of tremor after cumulative doses of FIG. 3. Mean FEV, after cumulative doses of salbutamol 
salbutamol inhaled via Turbuhaler (0) or pMD1 (0). inhaled via Turbuhaler (0) or pMD1 (0). 
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FIG. 2. Mean serum potassium concentration after 
cumulative doses of salbutamol inhaled via Turbuhaler 
(0) or pMD1 (0). 
Cumulative doses of 800 and 1600,~~g inhaled via 
Turbuhaler caused tremor in the other three patients, two 
of whom reported tremor also after 1600~8 inhaled via 
pMD1. Tremor was scored 1 (just perceivable) in all cases. 
The increase in objectively measured tremor was larger with 
Turbuhaler than with pMD1 (P<O.OOOl) (Fig. 1). Based 
on the three highest doses, the relative dose potency of 
Turbuhaler vs pMD1 was estimated to 2.3 with a 95% 
confidence interval of 1.54.4. 
SERUM POTASSIUM 
Serum potassium concentration increased after the first one 
to two doses of salbutamol and then declined by additional 
doses inhaled via Turbuhaler or pMD1 (Fig. 2). Based 
on the three highest doses, the relative dose potency of 
Turbuhaler rs pMDE was estimated to 2.0 with a 95% 
confidence interval of 1.3-3.6. The lowest serum potassium 





3.7 mmol 1 - ’ recorded after the highest cumulative dose 
(1600 pug) inhaled via Turbuhaler. 
ADVERSE EVENTS 
There were no reports of adverse events. There were no 
findings of clinical relevance on physical examination or in 
the clinical chemistry and haematology tests performed 
during or after the completion of the study. 
SRiROMETRY 
Baseline FEV, (mean & SD) was similar on the two study 
days (1.43 * 0.45 1 and 1.43 f 0.48 1). Individual changes 
from the first to the second study day varied from a 
reduction of 10.5% to an increase of 7.3%, indicating that 
the patients’ asthma was fairly stable throughout the study. 
After inhalation of salbutamol, FEV, increased successively 
up to 2.04 1 (Turbuhaler) and 1.92 1 (pMD1) after inhalation 
of a cumulative dose of 16OOpg (Fig. 3). Based on the 
horizontal distance between the parallel lines in Fig. 4, the 
relative dose potency of Turbuhaler vs pMD1 with regard 
to FEV, was estimated to 3.0 with a 95% confidence 
interval of 1.8-5.8. When based on FVC, the relative dose 
potency was estimated to 4.1 with a 95% confidence interval 
of 2.2-10.0. 
Discussion 
This investigation was performed to compare the safety and 
efficacy of a new formulation, salbutamol Turbuhaler, with 
that of a conventional pMD1 formulation containing the 
same active drug substance. When comparing different 
inhalers, it is preferable to use a double-blind and double- 
dummy technique. However, considering the number of 
inhalations taken at each dosing, especially at the higher 
dose levels, this was not feasible in the present study. Not 
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FIG. 4. Percentage increase in mean FEV, from mean 
baseline after cumulative doses of salbutamol inhaled via 
Turbuhaler (0) or pMD1 (0). Note that the cumulative 
doses are shown on a logarithmic scale. 
patients, but it would also have considerably prolonged the 
time between inhalations and assessments. 
The results of this study showed changes in extrapulmo- 
nary and bronchodilating responses to salbutamol inhaled 
Turbuhaler or pMD1. Serum potassium concentration was 
chosen as the primary safety variable because of its sensi- 
tivity and reproducibility (6). The hypokalaemic effect of 
salbutamol inhaled via Turbuhaler was found to corre- 
spond to that produced by twice the dose inhaled via 
pMD1. It was noticed, however, that the serum potassium 
concentration remained above the lower limit of the refer- 
ence range (3.5-5.0 mm011 - ‘) even after a cumulative dose 
of 16OOpg using either inhaler, and that it was not associ- 
ated with any symptoms of clinical relevance. Salbutamol 
inhaled via Turbuhaler caused a larger increase in 
heart rate, QTc interval and tremor than did equal 
doses of salbutamol inhaled via pMD1. The magnitude 
by which these variables were affected was small and 
considered to have no implications for normal, clinical use 
of salbutamol. 
Salbutamol inhaled via Turbuhaler produced a signifi- 
cantly greater bronchodilation than did equal doses of 
salbutamol inhaled via pMD1. The relative dose potency of 
salbutamol Turbuhaler vs salbutamol pMD1 was 3.0. This 
means that a Turbuhaler inhaler, on average, should con- 
tain about one-third of the nominal dose of pMD1 for the 
same bronchodilating effect to be achieved. This is in line 
with a recent single-dose study showing that the same 
bronchodilating effect produced by salbutamol inhaled 
via pMD1 can be obtained by half the dose inhaled via 
Turbuhaler (15). Despite the high cumulative dose of 
16OOpg of salbutamol in the present study, a maximum 
bronchodilating effect was not reached with either of the 
two inhalers. This absence of a dose-response plateau is 
consistent with results of several other &-agonists studies 
using cumulative dosing regimens (16,17). The mechanism 
behind the finding is assumed to be bronchodilation of 
airways after the initial doses with a cumulative technique 
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allowing increased penetration of succeeding doses. Since 
the first dose was inhaled at 8.30 a.m. and the last FEV, 
was measured at 11 a.m., it cannot be precluded that 
natural elevation of FEV, due to the circadian rhythm (18) 
may also have contributed to the increased bronchodilation 
with sequential doses. 
The higher potency of salbutamol Turbuhaler in produc- 
ing extrapulmonary and bronchodilating effects was prob- 
ably a result of a higher lung deposition, as the latter causes 
an increased concentration of active drug not only in the 
airways, but also in the systemic circulation (6). The 
beneficial effect of inhaled salbutamol seemed to outweigh 
the adverse effects when Turbuhaler was used instead of 
pMD1, as indicated by the relative dose potencies for 
salbutamol Turbuhaler vs salbutamol pMD1 of 3.0 and 4.1 
for FEV, and FVC, respectively, and 2.3 and 2.0 for tremor 
and serum potassium, respectively. From this, it follows 
that, within the dose range studied, salbutamol inhaled via 
Turbuhaler had an equal or better therapeutic ratio than 
salbutamol inhaled via pMD1. 
In conclusion, salbutamol Turbuhaler was found to be 
more potent than salbutamol pMD1 with regard to 
extrapulmonary effects in patients with moderate to severe 
asthma. The potency difference was numerically even more 
pronounced when considering the bronchodilating effect, 
suggesting that salbutamol Turbuhaler had a better thera- 
peutic ratio than salbutamol pMD1. Neither inhaler caused 
any clinically significant adverse effects at cumulative doses 
of salbutamol up to 16OOpg. 
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